Geben Sie eine Aktie oder eine Kryptowährung in der Suchleiste an, um eine Zusammenfassung zu erhalten
Neuca S.A.
NEUNEUCA S.A. engages in the wholesale distribution of pharmaceuticals in Poland. It operates through Wholesale Distribution of Medicines, Manufacture of Pharmaceuticals, Medical Operator, Clinical Trials, and Insurance Activities segments. The company owns and produces Rx, OTC medicines, dietary supplements, medical devices, dermocosmetics, hygiene products, personal protective equipment, as well as diagnostic and dressing materials under the Swiat Zdrowia, APTEO, GENOPTIM, CERA+ Solutions, and Kic Kic brand names to pharmacists, medical doctors, and patients. It provides medical care services, including prevention, diagnostics, treatment, and complementary services; and financing services, such as insurance, subscriptions, occupational medicine, preventive and medicine programmes, FFS, NFZ, public, private, and corporate payer services. In addition, the company offers TPA services, remote consultations, stationary visits, diagnostic tests, and occupational medicine services; operates a medical helpline and medical facilities; and offers medicine through apteline.pl, an e-commerce medical ordering site. Further, it engages in running clinical trials in the field of outsourcing clinical research and conducting clinical research centres; provision of insurance activities, including health insurance products. It also provides advertising and marketing services to pharmaceutical market entities; and logistics services for pharmaceutical manufacturers. The company was formerly known as Torfarm SA and changed its name to NEUCA S.A. in April 2010. NEUCA S.A. was founded in 1990 and is based in Torun, Poland. Address: Forteczna 35-37, Torun, Poland, 87-100
Analytics
Zielpreis von Wall Street
4 132.67 PLNKGV
22.0264Dividendenrendite
1.88 %Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Schlüsselzahlen NEU
Dividenden-Analyse NEU
Dividendenwachstum über 5 Jahre
103 %Kontinuierliches Wachstum
17 JahreAusschüttungsquote 5-Jahres-Durchschnitt
35 %Verlauf der Dividende NEU
Bewertung der Aktie NEU
Finanzen NEU
Ergebnisse | 2019 | Dynamik |